Skip to main content
logo
Lineage Cell Therapeutics, Inc. (LCTX)
NYSEAMERICAN: LCTX · Real-Time Price · USD
1.010
-0.010 (-0.98%)
Sep 11, 2026, 4:00 PM EDT - Market closed

Lineage Cell Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
13.0814.569.58.9514.74.34
Revenue Growth
19.87%53.24%6.19%-39.16%238.70%137.73%
Gross Profit
-7.51-3.32-3.31-7.4313.982.92
Operating Income
-26.85-21.78-21.48-21.2-22.52-49.21
Net Income
-32.26-63.53-18.61-21.49-26.27-43.02
Earnings Per Share
-0.19-0.28-0.09-0.12-0.15-0.26
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
50.8355.7847.8135.4957.8858.36
Total Debt
2.32.422.512.953.92.8
Net Cash (Debt)
48.5353.3645.2932.5453.9855.56
Net Cash Growth
20.92%17.82%39.19%-39.72%-2.84%47.22%
Net Cash Per Share
0.200.230.230.190.320.34

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-23.82-18.92-23.09-28.571.06-23.56
Capital Expenditures
-0.57-0.52-0.57-0.67-0.41-0.34
Free Cash Flow
-24.39-19.44-23.66-29.240.65-23.9
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
-57.36%-22.80%-34.81%-83.07%95.05%67.15%
Operating Margin
-205.23%-149.62%-226.11%-237.04%-153.17%-1133.63%
Pretax Margin
-285.75%-471.61%-195.62%-260.28%-175.56%-996.77%
Profit Margin
-246.58%-436.47%-195.91%-240.20%-178.69%-990.99%
FCF Margin
-186.42%-133.56%-249.05%-326.89%4.39%-550.59%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Forward PE
-45.6245.6245.6245.6245.62
P/FCF Ratio
----307.85-
PS Ratio
19.5227.8011.6621.3213.5395.13